RESEARCH
Published Evidence
RESEARCH
Published Evidence
Explore the Science Driving Innovation in Wound Healing
Chart updated: June 2025
Key Peer-Reviewed Publications
Title |
Authors (Journal, Year) |
Study Design |
Indication |
Summary of Evidence |
| Maximizing wound coverage in full-thickness skin defects: A randomized-controlled trial of autologous skin cell suspension and widely meshed autograft versus standard autografting | Henry et al. (J Trauma Acute Care Surg., 2024) | Experimental (Randomized Controlled Trial) | Surgical & traumatic wounds |
In patients with nonthermal full-thickness wounds, treatment with RECELL plus widely meshed autograft significantly reduced donor skin requirements by 27% compared to less widely meshed autografting. |
|
Demonstration of the safety and effectiveness of the RECELL® System combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries
|
Holmes et al. (Burns, 2019) | Experimental (Randomized Controlled Trial) | Burns |
In patients with mixed-depth burns (inclusive of full-thickness), treatment with RECELL plus widely meshed autograft significantly reduced donor skin requirements by 32% compared to less widely meshed autografting. |
|
A comparative study of the RECELL Device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries
|
Holmes et al. (J Burn Care Res., 2018) | Experimental (Randomized Controlled Trial) | Burns |
In patients with deep partial-thickness burns, treatment with RECELL alone significantly reduced donor skin requirements by 97.5% compared to 2:1 meshed autografting. The RECELL donor site resulted in significantly less pain, faster healing, and improved patient satisfaction. |
| A comparative study of spray keratinocytes and autologous meshed split-thickness skin graft in the treatment of acute burn injuries | Sood et al. (Wounds, 2015) | Experimental (Randomized Controlled Trial) | Burns | In patients with partial-thickness burns, treatment with RECELL alone resulted in decreased donor size and comparable healing outcomes compared to meshed autografting alone. Read it here |
| Analysis of real-world length of stay data and costs associated with use of autologous skin cell suspension for the treatment of small burns in U.S. centers | Carson et al. (Burns, 2023) | Observational | Burns |
Use of RECELL for small burns (<20% TBSA) in U.S. centers was associated with an average 2.1 day reduction in length of stay, translating to a $22,268 cost savings per patient. |
| Length of stay and costs with autologous skin cell suspension versus split-thickness skin grafts: Burn care data from US centers | Carter et al. (Adv Ther., 2022) | Observational | Burns |
Use of RECELL for burns up to 50% TBSA in U.S. centers was associated with an average 3.3 day reduction in length of stay, translating to a $36,949 cost savings per patient. |
| Cost-effectiveness of the use of autologous cell harvesting device compared to standard of care for treatment of severe burns in the United States |
Kowal et al. (Adv Ther., 2019)
|
Foundational Research | Burns |
Economic models demonstrate that hospital length of stay accounts for up to 70% of cost reductions, with estimated per-patient savings ranging from $31,000 to over $150,000, and projected annual savings of $5.3 to $6.8 million for a representative U.S. burn center treating 200 patients. |
| Autologous skin cell suspension for full-thickness skin defect reconstruction: Current evidence and health economic expectations | Kahn et al. (Adv Ther., 2024) | Narrative Review | Surgical & traumatic wounds |
This article discusses the cost benefits that may be anticipated with the use of RECELL for surgical & traumatic full-thickness wounds. |
| Biological attributes required for epidermal regeneration: Evaluation of the next-generation autologous cell harvesting device | Bush et al. (Int Wound J., 2024) | Foundational Research | – |
The RECELL GO device aids in the preparation of a comparable skin cell suspension to the previous device with improved standardization and reduced variability in cell count. |
| Wound healing and scar patterning after addition of autologous skin cell suspension to meshed grafts | Collins et al. (J Surg Res., 2024) | Foundational Research | Surgical wounds |
In porcine full-thickness wounds treated with 3:1 meshed autograft, the addition of RECELL significantly increased rate of re-epithelialization of interstices at early time points. |
| Sprayed keratinocyte suspensions accelerate epidermal coverage in a porcine microwound model | Navarro et al. (J Burn Care Rehabil., 2000) | Foundational Research | Surgical wounds |
In porcine full-thickness wounds treated with 3:1 meshed autograft, the addition of RECELL resulted in faster and better quality of epithelialization at the cellular level. |
Title |
Authors (Journal, Year) |
Study Design |
Indication |
Summary of Evidence |
| A randomized, controlled trial comparing PermeaDerm® to Mepilex Ag® in the treatment of adult and pediatric partial-thickness burns | Greenhalgh et al. (J Burn Care Res., 2025) | Experimental (Randomized Controlled Trial) | Burns |
In (mostly pediatric) patients with partial-thickness burns, treatment with PermeaDerm significantly reduced the odds of needing a dressing change compared to Mepilex Ag. |
| Initial experience using a biosynthetic wound matrix for full-thickness wound temporization | Akpunonu et al. (J Surg., 2025) | Observational | Surgical wounds |
PermeaDerm performed as a viable option for temporizing full-thickness wounds, The authors concluded that PermeaDerm is an effective alternative to allograft, delivering similar clinical outcomes while offering advantages like simplified storage, reduced cost, easier application, and optimized management. |
| Use of a bioactive matrix glove in the treatment of pediatric hand burns: a case series | Julian et al. (J Wound Care, 2024). | Observational | Burns |
In pediatric patients with partial-thickness hand burns, the PermeaDerm glove resulted in successful healing with minimal scarring, preserved joint mobility, and minimal need for dressing changes. |
| Preliminary study of wound oxygenation comparing skin substitutes and dressings | Woodroof et al. (Eplasty, 2023) | Foundational Research | – |
PermeaDerm transferred oxygen significantly faster than Integra® Dermal Regeneration Template and NovoSorb™ Biodegradable Temporizing Matrix, suggesting its potential to enhance wound healing by improving oxygenation delivery. |
| In vitro characterization of variable porosity wound dressing with anti-scar properties | Woeller et al. (Eplasty, 2018) | Foundational Research | – |
PermeaDerm supported cell growth and reduced scar-associated myofibroblast formation and inflammatory cytokines. |
| Evaluating a variable porosity wound dressing with anti-scar properties in a porcine model of wound healing | Woeller et al. (Eplasty, 2018) | Foundational Research | Surgical wounds |
In full-thickness porcine wounds, those treated with PermeaDerm healed more effectively and showed potential to reduce excessive scar formation compared to those not treated. |
| Evolution of a temporary biosynthetic skin substitute: A preliminary study | Woodroof et al. (Eplasty, 2015) | Foundational Research | Surgical wounds |
PermeaDerm demonstrated better control of inflammation, reduced scarring markers, and superior cell growth and migration compared to Biobrane®. |
Title |
Authors (Journal, Year) |
Study Design |
Indication |
Summary of Evidence |
| A bovine dermal collagen matrix (BDCM) advances readiness to autografting: A case series | Akpunonu et al. (J Surg., 2025) | Observational | Surgical wounds |
Cohealyx facilitated wound bed vascularization within 5-10 days, demonstrating its clinical potential as a dermal matrix option to expedite graft-readiness. |
| Bovine dermal collagen matrix promotes vascularized tissue generation supporting early definitive closure in full-thickness wounds: A pre-clinical study | Bush et al. (Cureus, 2025) | Foundational Research | Surgical wounds |
In full-thickness porcine wounds, Cohealyx supported rapid cellular infiltration and vascularized tissue formation, supporting autograft readiness at Day 7 and earlier definitive closure compared to Integra® Bilayer Wound Matrix and Kerecis®. |